{"id":"low-dose-anrikefon","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Leukopenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anrikefon acts as an interferon-alpha (IFN-α) analog, which binds to interferon-alpha receptors on cell surfaces to activate JAK-STAT signaling pathways. This leads to upregulation of interferon-stimulated genes, enhanced natural killer cell activity, and increased antigen presentation. The drug exhibits antiviral, antiproliferative, and immunomodulatory effects.","oneSentence":"Anrikefon is an interferon-alpha derivative that enhances innate immune responses and has antiviral and antiproliferative properties.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:53:19.863Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"},{"name":"Certain viral infections"}]},"trialDetails":[{"nctId":"NCT07246785","phase":"PHASE4","title":"Anrikefon-based Patient-controlled Intravenous Analgesia After Laparoscopic Surgery","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-12-25","conditions":"Laparoscopic Surgery, Visceral Pain, Postoperative, Anrikefon","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low-dose anrikefon-based patient-controlled analgesia"],"phase":"marketed","status":"active","brandName":"Low-dose anrikefon","genericName":"Low-dose anrikefon","companyName":"Peking University First Hospital","companyId":"peking-university-first-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anrikefon is an interferon-alpha derivative that enhances innate immune responses and has antiviral and antiproliferative properties. Used for Chronic hepatitis B, Chronic hepatitis C, Certain viral infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}